AP is the leading pancreatic condition associated with the onset of type 3c diabetes mellitus (T3cDM) [4,5]—a secondary form of diabetes caused by exocrine pancreatic dysfunction—through mechanisms such as islet cell destruction due to inflammation and necrosis, altered insulin signaling [6], Il-6-mediated insulin resistance [7], and enhanced lipolysis [7], with longitudinal data showing that up to 40% of patients develop diabetes within five years after a first AP episode [8]. This evidence concerns the gene IL6 and diabetes mellitus.